Global Insulin Detemir Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Insulin Detemir market size was valued at US$ 5748 million in 2025 and is forecast to a readjusted size of US$ 2750 million by 2032 with a CAGR of -10.0% during review period.
Insulin Detemir is a long-acting basal insulin analog and a soluble biologic medicine manufactured through recombinant DNA expression in Saccharomyces cerevisiae followed by chemical modification. Compared with human insulin, the threonine residue at position B30 is removed and a C14 myristic fatty-acid side chain is attached to lysine at position B29. This molecular design allows the product to remain soluble after subcutaneous injection while prolonging action through self-association and reversible albumin binding, thereby slowing absorption and extending systemic exposure. Commercial formulations are typically clear, colorless, aqueous injections at 100 units/mL, commonly supplied as 3 mL cartridges or pre-filled pens containing 300 units each, with excipients such as glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, and water for injections. The product belongs to the basal insulin/long-acting insulin analog category and is mainly used for background glycemic control in type 1 and type 2 diabetes, either alone or in combination with prandial insulin, oral antidiabetic agents, or GLP-1 receptor agonists. Industrial production requires strong capabilities in recombinant expression and purification, structural modification consistency, sterile fill-finish, cold-chain handling, delivery-device compatibility, potency and impurity control, as well as pharmaceutical and clinical comparability evaluation. Manufacturers capable of supplying this product are typically large biologics companies or specialist insulin producers with established industrial know-how.
The global diabetes patient base continues to expand. The 2025 IDF figures indicate about 589 million adults aged 20-79 living with diabetes worldwide, with a projection of 853 million by 2050, while WHO continues to describe diabetes as a major global health burden. Against this backdrop, basal insulin remains a core therapy category for type 1 diabetes and for part of the type 2 diabetes population, so total basal-insulin demand is not shrinking. For Insulin Detemir specifically, however, the practical opportunity is no longer large-scale new patient penetration, but rather stable switching of existing patients, localized supply continuity, hospital and retail substitution management, and refined service in markets where registrations and inventories still remain. For companies with biologics process capability, sterile fill-finish, cold-chain infrastructure, and device-integration experience, Insulin Detemir may still retain short-term value in regulatory, supply, and transition-management settings.
From a medium- to long-term perspective, the constraints on Insulin Detemir are stronger than the opportunities. Novo Nordisk has confirmed the permanent withdrawal of Levemir in the United States, EMA has confirmed that the affected EU presentations will be discontinued before the end of 2026, and UK communications also state that no new patients should be started. Public company websites, regulatory databases, and official product information do not show an established follow-on marketed biosimilar landscape for Insulin Detemir in major regulated markets, meaning supply is highly concentrated in a single operating subject. As a result, market size, manufacturing continuity, regulatory maintenance, and commercial access are all strongly influenced by one company’s portfolio decisions. At the same time, clinical and commercial focus in basal insulin is continuing to move toward insulin glargine, insulin degludec, and longer-duration products, leaving Insulin Detemir at a disadvantage in prescribing priority, dosing frequency, channel economics, and resource allocation.
Downstream demand is shifting from “new patient initiation” to “existing patient maintenance and therapeutic switching.” Hospitals are likely to place greater weight on supply continuity, reimbursement access, hypoglycemia management, dosing convenience, and training burden, which favors basal insulins with more stable supply and longer lifecycle visibility. Retail and community channels are more focused on post-switch glucose variability, body-weight effects, learning costs for delivery devices, and prescription refill convenience. Short-term residual demand will remain among pediatric patients, pregnancy-related use, and people highly attached to specific brands or devices, but over 2026-2032 the real downstream pattern for Insulin Detemir is more likely to be inventory depletion, structural substitution, and regimen migration rather than independent and sustainable market expansion.
This report is a detailed and comprehensive analysis for global Insulin Detemir market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Insulin Detemir market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Insulin Detemir market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Insulin Detemir market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Insulin Detemir market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Insulin Detemir
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Insulin Detemir market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Insulin Detemir market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Resuable
Disposable
Market segment by Dosage Presentation
Solution for Injection in Vial
Solution for Injection in Cartridge
Solution for Injection in Pre-filled Pen
Others
Market segment by Value-chain Delivery Level
Insulin Detemir Drug Substance
Bulk Drug Product Solution
Finished Drug Product
Drug-Device Combination Product
Others
Market segment by Commercial Pack Configuration
Single-unit Pack
Multi-unit Pack
Pen Pack with Needles
Others
Market segment by Application
Hospital
Clinic
Home Use
Others
Major players covered
Novo Nordisk
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Insulin Detemir product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Insulin Detemir, with price, sales quantity, revenue, and global market share of Insulin Detemir from 2021 to 2026.
Chapter 3, the Insulin Detemir competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Insulin Detemir breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Insulin Detemir market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Insulin Detemir.
Chapter 14 and 15, to describe Insulin Detemir sales channel, distributors, customers, research findings and conclusion.